1. A method for detection of carcinomas or their precursor lesions comprising: a) obtaining a biological test sample from an individual; b) determining the level of DNase-X polypeptide or nucleic acid in the test sample; c) comparing the level of DNase-X molecules within said test sample to the level of DNase-X within a corresponding control sample; and d) classifying a test sample exhibiting an increased level of DNase-X polypeptide or nucleic acid relative to the level of DNase-X in the control sample as indicative of the presence of a carcinoma or precursor lesion.
2. The method according to claim 1, wherein the detection of the DNase-X polypeptide or nucleic acid comprises detecting accessible regions of the polypeptide or nucleic acid.
3. The method according to claim 1, wherein the test sample is blood, plasma, serum, liquor, lymph, bone marrow, swabs, washes, lavages, secretions, transsudates, exudates, sputum, stool, urine, semen, cell- and tissue-samples, punctuates or biopsies.
4. The method according to claim 1, wherein the carcinoma is cancer of the head and the neck, cancer of the respiratory tract, cancer of the gastrointestinal tract, cancer of the skin and its appendages, cancer of the central and peripheral nervous system, cancer of the urinary system, cancer of the reproductive system, cancer of the endocrine system, cancer of the soft tissues and bone, cancer of the lymphopoietic and hematopoietic system, breast cancer, lung cancer, cervical cancer, colorectal cancer or anogenital cancer.
5. The method according to claim 1, wherein the detection of the level of the DNase-X polypeptide or nucleic acid is carried out using at least one probe specifically binding to the marker polypeptide or nucleic acid to be detected.
6. The method according to claim 5, wherein the at least one probe is detectably labeled.
7. The method according to claim 6, wherein the label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, a biologically relevant binding structure such as biotin or digoxygenin and an enzyme.
8. The method according to claim 5, wherein the at least one probe is an antibody, an antigen-binding fragment of an antibody, a peptidomimetic comprising an antigen-binding epitope or a mini-antibody.
9. The method according to claim 8, wherein the detection comprises an immuno-cytochemical detection procedure.
10. The method according to claim 5, wherein the at least one probe is a nucleic acid.
11. The method according to claim 10, wherein the detection of the level of DNase-X using the at least one probe comprises a nucleic acid amplification reaction.
12. A method of identifying and obtaining a drug candidate for treatment of carcinomas and their precursor lesions comprising the following steps:
a) contacting a DNase-X polypeptide with said drug candidate to be screened, in the presence of components capable of providing a detectable signal in response to DNase-X activity under conditions to allow continued DNase-X activity; and
b) detecting presence or absence of a signal or increase of the signal generated from DNase-X activity, wherein the presence or increase of the signal is indicative of a putative drug.
13. Kit for the treatment of carcinomas and their precursor lesions, comprising a drug as identified in claim 12.
14. A pharmaceutical composition useful for treating carcinomas and their precursor lesions comprising at least a putative drug as identified in claim 12.
15. The pharmaceutical composition according to claim 14, wherein the carcinoma is cancer of the head and the neck, cancer of the respiratory tract, cancer of the gastrointestinal tract, cancer of the skin and its appendages, cancer of the central and peripheral nervous system, cancer of the urinary system, cancer of the reproductive system, cancer of the endocrine system, cancer of the soft tissues and bone, cancer of the lymphopoietic and hematopoietic system, breast cancer, anogenital cancer or colorectal cancer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for preparing a medical prosthetic device or medical implant, said method comprising:
subjecting surface parts of a metal material selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy to an electrolysis treatment in the presence of one or more biomolecule(s), said metal material constituting a cathode during said electrolysis, in which method a layer of a corresponding hydride material selected from the group consisting of titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium andor vanadium hydride is formed on said surface parts and the biomolecule(s) become associated with the hydride material,
wherein the electrolysis treatment is carried out in the presence of an electrolyte comprising the one or more biomolecule(s) having a net positive charge in the electrolyte; and
wherein the one or more biomolecule(s) is not collagen.
2. The method as claimed in claim 1, wherein said medical prosthetic device or implant is a dental implant.
3. The method as claimed in claim 1, wherein said metal material is titanium.
4. The method according to claim 1, wherein the one or more biomolecule(s) is non-covalently associated with the device.
5. The method according to claim 1, wherein said electrolysis treatment is carried out at a pH between 0 and 10.
6. The method according to claim 1, wherein said electrolysis treatment is carried out at a pH between 2 and 5.
7. The method according to claim 1, wherein said electrolysis treatment is carried out in the presence of an electrolyte having an ionic strength between 0.01M and 10M.
8. The method according to claim 1, wherein said electrolysis treatment is carried out at a temperature of between 0\xb0 C. and 100\xb0 C.
9. The method according to claim 1, wherein said electrolysis treatment is carried out at a temperature of between 20\xb0 C. and 80\xb0 C.
10. The method according to claim 1, wherein the electrolysis treatment is carried out at a voltage between 0.1 and 1000 volts.
11. The method according to claim 1, wherein the electrolysis treatment is carried out at a voltage below 10 volts.
12. The method according to claim 1, wherein the electrolysis treatment is carried out at a current density between about 0.1 mA per cm2 and 1 A per cm2.
13. The method according to claim 1, wherein the electrolysis treatment is carried out at a current density of about 1 mAcm2.
14. The method according to claim 1, wherein the electrolysis treatment is carried out for between about 0.5 and 24 hours.
15. The method according to claim 1, wherein the electrolysis treatment is carried out under aseptic or sterile conditions.
16. The method according to claim 1, wherein the one or more biomolecule(s) exhibits a net positive charge dissolved in a salt solution having an ionic strength within the range of from 0.01 to 10M, a temperature within the range of from 0 to 100\xb0 C., and a pH within the range of from 0 to 10.
17. The method according to claim 1, wherein the one or more biomolecule(s) is an ampholyte.
18. The method according to claim 1, wherein the one or more biomolecule(s) is selected from the group consisting of natural, recombinant or synthetic bio-adhesives; natural, recombinant or synthetic cell attachment factors; natural, recombinant or synthetic biopolymers; natural, recombinant or synthetic blood proteins; natural, recombinant or synthetic enzymes; natural, recombinant or synthetic extracellular matrix proteins; natural, recombinant or synthetic extracellular matrix biomolecules; natural, recombinant or synthetic growth factors; natural, recombinant or synthetic hormones; natural, recombinant or synthetic peptide hormones; natural, recombinant or synthetic deoxyribonucleic acids (DNA); natural, recombinant or synthetic ribonucleic acids (RNA); natural, recombinant or synthetic receptors; natural, recombinant or synthetic enzyme inhibitors; drugs; biologically active cations; natural, recombinant or synthetic peptides; natural, recombinant or synthetic proteins; natural or synthetic vitamins; adenosine monophosphate (AMP); adenosine diphosphate (ADP; adenosine triphosphate (APT); marker biomolecules; amino acids; fatty acids; nucleosides; nucleotides (RNA and DNA bases); and sugars.
19. The method according to claim 1, wherein the one or more biomolecule(s) is a drug.
20. The method according to claim 19, wherein the one or more biomolecule(s) is a statin.
21. The method according to claim 1, wherein the electrolysis treatment is performed in a two-chamber cell containing the cathode and anode in separate chambers.
22. The method according to claim 1, wherein the one or more biomolecule(s) is present in a concentration ranging from 1 pgmL to 50 mgmL.
23. The method according to claim 1, wherein the one or more biomolecule(s) is present in a concentration ranging from 10 pgmL to 1 mgmL.
24. A method for preparing a medical prosthetic device or medical implant, said method comprising:
subjecting surface parts of a metal material selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy to an electrolysis treatment in the presence of one or more biomolecule(s), said metal material constituting a cathode during said electrolysis, in which method a layer of a corresponding hydride material selected from the group consisting of titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium andor vanadium hydride is formed on said surface parts and the biomolecule(s) become associated with the hydride material,
wherein the electrolysis treatment is carried out in the presence of an electrolyte comprising the one or more biomolecule(s) having a net positive charge in the electrolyte; and
wherein the electrolysis is performed for a time sufficient to form a hydride layer;
wherein the one or more biomolecule(s) is not collagen.